Date: 2017-05-02
Type of information: Licensing agreement
Compound: KL1333
Company: Neurovive Pharmaceutical (Sweden) Yungjin Pharm (South Korea)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: licensing
Action mechanism:
- NAD+ modulator. KL1333 is a potent modulator of the cellular levels of NAD+, a central coenzyme in the cell’s energy metabolism. KL1333 has in preclinical studies been demonstrated to increase mitochondrial energy output, reduce lactate accumulation, diminish the formation of free radicals, and to have long-term beneficial effects on energy metabolism. It is in clinical development stage for chronic oral treatment of primary genetic mitochondrial disorders such as MELAS, KSS, CPEO, PEO, Pearson, MERRF and Alpers syndrome. It’s mode of action is complementary to that of NVP015, which is intended to alleviate acute episodes of energy crises in genetic mitochondrial disorders with dysfunction in respiratory complex I and to NVP025, intended to protect the mitochondria in skeletal muscle from dysfunctional calcium handling and consequential muscle wasting.
Disease: genetic mitochondrial disorders
Details:
- • On May 2, 2017, NeuroVive Pharmaceutical and Yungjin Pharm Corporation jointly announced that they have entered into a global licensing agreement on Yungjin Pharm’s compound KL1333 for genetic mitochondrial disorders.
Yungjin Pharm has granted NeuroVive exclusive global rights to develop and commercialize KL1333 worldwide, except for Korea and Japan, where Yungjin Pharm retains all commercial and marketing rights. Both companies will develop KL1333 in their respective territories, primarily for the treatment of genetic mitochondrial disease.Yungjin Pharm has received an IND and a clinical study approval in Korea, and the phase I clinical study is scheduled to start within a couple of months. NeuroVive plans to initiate a complementary European and/or US based phase I study in early 2018.
Financial terms:
- Under the terms of the agreement, NeuroVive will pay Yungjin Pharm upfront payments of $ 1 millionat signing, $ 1 million one year after the signing and an additional $1 million after the completion of a successful phase I clinical trial. Further payments will be paid upon successful achievement of clinical development (in total $ 12 ) market and reimbursement approval (in total $ 42 million) milestones. In addition, Yungjin Pharm will also be eligible to receive approval and sales milestone payments and tiered single to low double-digit royalties on future net sales.
Latest news:
- • On June 27, 2017, NeuroVive Pharmaceutical and Yungjin Pharm announced that the clinical phase I study of KL1333 has started in Korea and that the first healthy volunteer has been enrolled.
Is general: Yes
